Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Founded in 2016, PEN has quickly become one of the largest and most successful home services companies in the nation with a footprint across multiple states. With a focus on customer satisfaction and strategic business planning, PEN has grown into a multi-product business that has increased revenue year over year and expanded its reach into new markets across the United States.
SOLAR POWERHOUSE > HVCW Announces the Merger with Pacific Energy Network
12:06 pm ET August 11, 2022 (Accesswire) Print
NEW YORK, NY / ACCESSWIRE / August 11, 2022 / On July 15, 2022, Harrison, Vickers & Waterman, Inc., a Wyoming corporation ("HVCW"), PEN Merger Sub, LLC, a California limited liability company ("Merger Sub"), and Pacific Energy Network LLC, a California limited liability company ("PEN"), entered into an Agreement and Plan of Merger (the "Merger Agreement").
On August 8, 2022 Harrison Vickers & Watermain, Inc and Pacific Energy (doing business as Modern Pro Solutions) finalized and closed on the Merger Agreement.
"We believe there is a lot of opportunity in front of us and being public will help us maximize those opportunities for the benefit of the shareholders", stated Bobby Tetsch, CEO of HVCW.
Pacific Energy Network (dba Modern Pro Solutions) is a California based parent company of several subsidiary LLC's that manage solar, roofing, HVAC, security, distribution, consulting, lead generation, marketing, sales, data, software and mortgage divisions.
Founded in 2016, PEN has quickly become one of the largest and most successful home services companies in the nation with a footprint across multiple states. With a focus on customer satisfaction and strategic business planning, PEN has grown into a multi-product business that has increased revenue year over year and expanded its reach into new markets across the United States.
For further information, please visit the Modern Pro Solutions website at www.joinmps.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
The statements contained in this news release which are not historical facts may be "forward-looking statements" that involve risks and uncertainties which could cause actual results to differ materially from those currently anticipated. For example, statements that describe PEN's hopes, plans, objectives, goals, intentions, or expectations are forward-looking statements. The forward-looking statements made herein are only made as of the date of this news release. Numerous factors, many of which are beyond HVCW and PEN's control, will affect actual results. HVCW and PEN undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. This news release should be read in conjunction with HVCW's most recent financial reports and other filings posted with the OTC Markets and/or the U. S. Securities and Exchange Commission by HVCW.
For More Information Contact:
Investor Relations
TEN Associates
Tom Nelson
480-326-8577
SOURCE: Harrison, Vickers & Waterman, Inc.
Congrats on this IPO . TGL a stratospheric runner! I'm checking for any IPO's launching tomorrow. Friday 8/12/22.
JMP Securities Sticks to Their Buy Rating for eFFECTOR Therapeutics (EFTR)
August 11 2022 - 12:15AM
TipRanks
Share On Facebook
In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on eFFECTOR Therapeutics (EFTR - Research Report), with a price target of $5.00. The company's shares closed yesterday at $0.73.According to TipRanks, Benjamin is an analyst with an average return of -6.0% and a 37.63% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Blueprint Medicines, CTI BioPharma, and Incyte.eFFECTOR Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $25.00, a 3,303.68% upside from current levels. In a report released yesterday, Credit Suisse also maintained a Buy rating on the stock with a $10.00 price target.
https://www.tipranks.com/news/blurbs/jmp-securities-sticks-to-their-buy-rating-for-effector-therapeutics-eftr?utm_source=advfn.com&utm_medium=referral
>>>>> # 45 <<<<<
Vacasa Shares Soar 36% on Higher 2022 Outlook Following Strong Demand
5:18 pm ET August 10, 2022 (Dow Jones) Print
By Denny Jacob
Vacasa Inc. shares soared 36% to $4.13 in after-hours trading Wednesday after the company raised its full-year outlook on the heels of strong demand in recent months.
The vacation rental property management services provider guided for full year 2022 revenue between $1.17 billion to $1.19 billion, up from its prior forecast of $1.13 billion to $1.18 billion. The company also guided for adjusted earnings before interest, taxes, depreciation and amortization between a loss of $7 million to zero, narrower than its previous forecast of an adjusted Ebitda between a loss of $14 million to a loss of $21 million.
Vacasa guided for revenue between $385 million to $395 million and adjusted Ebitda between $55 million to $60 million in the third quarter.
"We experienced strong guest demand during the second quarter and July that has continued into August," Chief Executive Matt Roberts said.
The company also posted second-quarter results. Vacasa swung to a gain of $9.9 million, or 2 cents a share, for the quarter ended June 30, from a loss of $19.9 million, or no earnings per-share, a year earlier. Analysts polled by FactSet expected a loss of 18 cents a share.
Revenue rose to $310.3 million from $237.6 million. Analysts polled by FactSet expected $285.5 million.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
August 10, 2022 17:18 ET (21:18 GMT)
Vacasa, Inc. is engaged in providing vacation rental management platform in North America. The Company's integrated technology and operations platform optimizes vacation rental income and home care for homeowners and offers guests with services. The Company's Vacasa.com, its Guest app helps guests to search, discover and book properties. The Guests from around the world utilize the Company’s technology and services to search and book Vacasa-listed properties in destinations throughout North and Central America. The Company provides home care solutions provided directly to homeowners such as home maintenance and improvement services, linen and towel supply programs, supplemental housekeeping services, and other related services. The Company also provides other offerings such as real estate brokerage services and residential management services to community and homeowner associations. It has approximately 400 Vacasa- listed destinations throughout North America, Belize and Costa Rica.
LOL, > Trump , Joe Pesci & GoodFellas!
EFTR > . 84
EFTR .72 up 10% > price target of $26.00.
I said, here she come now singin', "Moni, Moni"
Shoot 'em up, come on, Moni, Moni
Don't stop cookin', 'cause I feel too good, yeah
Nice and warm now, yeah
I said, don't stop now, well come on, Moni, come on, yeah
I said, yeah (yeah), yeah (yeah), yeah (yeah), yeah (yeah), yeah (yeah)
Lyrics by Tommy James & The Shondells > 1968
Ratcheting up along with R*SLS.
RSLS @ .62 > The company said it expects U.S. commercial sales to begin in September 2022.
Investors are forward looking. The company said it expects U.S. commercial sales to begin in September 2022.
ReShape Lifesciences Shares Jump After FDA Clearance for GIBI Calibration Tube
12:25 pm ET August 10, 2022 (Dow Jones) Print
By Chris Wack
ReShape Lifesciences Inc. shares rose 33% to 64 cents a share after the company said it received U.S. Food and Drug Administration 510(k) clearance for its disposable gastro intestinal balloon indicator calibration tube for use in gastric and bariatric surgical procedures.
The company said it expects U.S. commercial sales to begin in September 2022.
The product includes three new sizes for bariatric procedures such as laparoscopic sleeve gastrectomy, gastric bypass and adjustable gastric banding.
The stock hit its 52-week low of 46 cents a share July 27.
In @ .90 > Out @ 1.06 > The company sales are almost non-existent.
Therapeutics is a Strong Buy with an average price target of $26.00
.65 in AH > oversold! > Mizuho Securities Sticks to Its Buy Rating for eFFECTOR Therapeutics (EFTR)
August 09 2022 - 08:25PM
TipRanks
Share On Facebook
In a report released yesterday, Mara Goldstein from Mizuho Securities maintained a Buy rating on eFFECTOR Therapeutics (EFTR - Research Report), with a price target of $20.00. The company's shares closed yesterday at $0.65.According to TipRanks, Goldstein is a 3-star analyst with an average return of 2.4% and a 36.62% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Nektar Therapeutics, IN8bio, and Incyte.Currently, the analyst consensus on eFFECTOR Therapeutics is a Strong Buy with an average price target of $26.00.See today’s best-performing stocks on TipRanks >>The company has a one-year high of $40.42 and a one-year low of $0.75.
https://www.tipranks.com/news/blurbs/mizuho-securities-sticks-to-its-buy-rating-for-effector-therapeutics-eftr-2?utm_source=advfn.com&utm_medium=referral
Verona Pharma Announces Proposed Underwritten Public Offering Of 10M ADSs
4:42 pm ET August 9, 2022 (Benzinga) Print
Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announced a proposed underwritten public offering of 10 million American Depositary Shares ("ADSs"), each representing eight ordinary shares of Verona Pharma, nominal value £0.05 per share (the "Offering"). All ADSs in the Offering will be offered by Verona Pharma. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the offering. In addition, Verona Pharma intends to grant the underwriters of the Offering a 30-day option to purchase up to an additional 1.5 million ADSs at the public offering price, less the underwriting discount and commission.
Paul Pelosi Jr goes from fraud scheme to fraud scheme...
https://www.dailymail.co.uk/news/article-9827893/Nancy-Pelosis-son-Paul-involved-FIVE-companies-probed-feds.html
Amazing video with eerie music, slow-motion sequences!
TOMDF IS A GREAT $$$$$ OPPORTUNITY.
Good info! Thank you! .10 + happening this week!
"It’s automation at Provista Diagnostics should also set it up to be a go-to for customers looking for monkeypox testing. Todos shares have been under pressure from a convertible toxic noteholder, which may have finally sold his last share. Thus the stock is set up for a fundamental and technical move upwards and with their billion-dollar subsidiary, the sky is the limit."
"TOMDF shares are theoretically undervalued by a factor of 44x just according to their ownership in 3CL Pharma. As with APDN, Todos’ Provista Diagnostics lab is picking up business and has become more profitable over time."
Biden administration, & Justice Dept. & FBI using banana republic tactics.
IPO REGISTRATION TO NASDAQ > MULTI-DOLLARS IN THE WORKS
S-1 Filed for Todos Medical > IPO REGISTRATION > Nasdaq/NYSE.
JULY 28, 2022
https://docoh.com/filing/1645260/0001493152-22-020454/TOMDF-S1
Exactly! Our crew forecasting .25 to .30 by August 26. 2022
Todos Medical Ltd. is an in vitro diagnostics company. It is focused on the development of novel blood tests for the early detection of cancer and Alzheimer's disease, and the distribution of comprehensive solutions for COVID-19 screening. It is also involved in the activities of breast cancer test, such as TM-B1 and TM-B2. The company was founded by Rami Zigdon and Udi Zelig on April 22, 2010 and is headquartered in Tel Aviv, Israel.
Gross margins + 32.9% > Net income up +307% >
Company revenues to ramp up with NJ / NY testing starting next week.
Revenue per employee is $408k . TOMDF has moved up 200% over last 5 sessions ( MarketWatch).
Saliva-based sample collection is currently undergoing intense research that could open up the potential for testing of asymptomatic or very early-stage patients at high risk of severe disease (such as immunocompromised patients) that could result in earlier diagnosis and early intervention with therapeutic drugs such as Tecovirimat .
Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP-certified laboratory Provista Diagnostics has initiated a validation plan for PCR-based MonkeyPox testing. Under the plan, the Company is validating multiple PCR assays for MonkeyPox and will launch the most sensitive for lesion-based and saliva-based sample collections. While lesion-based testing is the current standard of care according to CDC guidelines, saliva-based sample collection is currently undergoing intense research that could open up the potential for testing of asymptomatic or very early-stage patients at high risk of severe disease (such as immunocompromised patients) that could result in earlier diagnosis and early intervention with therapeutic drugs such as Tecovirimat (TPOXX). TPOXX is an investigational drug candidate, and currently only available under an expanded access Investigational New Drug (EA-IND) protocol. The MonkeyPox tests are being developed as Laboratory Developed Tests (LDTs). A recent peer-reviewed article describing strong correlation of the sensitivity of lesion and saliva-based PCR testing was recently published in the journal Eurosurveillance: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2022.27.28.2200503
“The significant investment we made to automate PCR testing at Provista to maximize COVID testing capacity can now be partially redeployed towards MonkeyPox as we prepare to help the nation scale-up MonkeyPox testing capacity to meet the emerging public health crisis,” said Gerald E. Commissiong, President & CEO of Todos Medical.
About Todos Medical Ltd.
Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that examines cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos’ two internally developed cancer-screening tests, TMB-1 and TMB-2 have received a CE mark in Europe. Todos recently acquired U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing, Long COVID Panel, and Provista's proprietary commercial-stage Videssa® breast cancer blood test.
CDC still has to authorize saliva testing for New Jersey. Could take several weeks.
Once Biden signs the bill, we'll see increased momentum for SIRC share price. SIRC revenues growing exponentially!
Up 157% on heavy volume.
BNSO
These Hong Kong super low floaters have been so predictable for the last week . BNSO may see 20.00+ this week.
BNSO @ 12.62